Klotho and chronic kidney disease

Ming C Hu, Makoto Kuro-o, Orson W Moe

Research output: Chapter in Book/Report/Conference proceedingChapter

92 Citations (Scopus)

Abstract

Through alternative splicing, Klotho protein exists both as a secreted and a membrane form whose extracellular domain could be shed from the cell surface by secretases and released into the circulation to act as endocrine factor. Unlike membrane Klotho which functions as a coreceptor for fibroblast growth factor-23 (FGF23) to modulate FGF23 signal transduction, soluble Klotho is a multifunction protein present in the biological fluids including blood, urine and cerebrospinal fluid and plays important roles in antiaging, energy metabolism, inhibition of Wnt signaling, antioxidation, modulation of ion transport, control of parathyroid hormone and 1,25(OH) 2 VD 3 production, and antagonism of renin-angiotensin- aldosterone system. Emerging evidence from clinical and basic studies reveal that chronic kidney disease is a state of endocrine and renal Klotho deficiency, which may serve as an early biomarker and a pathogenic contributor to chronic progression and complications in chronic kidney disease including vascular calcification, cardiac hypertrophy, and secondary hyperparathyroidism. Supplementation of exogenous Klotho and/or upregulation of endogenous Klotho production by using rennin angiotensin system inhibitors, HMG CoA reductase inhibitors, vitamin D analogues, peroxisome proliferator-activated receptors- gamma agonists, or anti-oxidants may confer renoprotection from oxidation and suppression of renal fibrosis, and also on prevention or alleviation of complications in chronic kidney disease. Therefore, Klotho is a highly promising candidate on the horizon as an early biomarker, and as a novel therapeutic agent for chronic kidney disease.

Original languageEnglish (US)
Title of host publicationPhosphate and Vitamin D in Chronic Kidney Disease
PublisherS. Karger AG
Pages47-63
Number of pages17
Volume180
ISBN (Print)9783318023701, 9783318023695
DOIs
StatePublished - May 2 2013

Fingerprint

Chronic Renal Insufficiency
Angiotensins
Biomarkers
Chymosin
Cerebrospinal fluid
Membranes
Vascular Calcification
Kidney
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Amyloid Precursor Protein Secretases
Signal transduction
Secondary Hyperparathyroidism
PPAR gamma
Ion Transport
Alternative Splicing
Cardiomegaly
Renin-Angiotensin System
Aldosterone
Parathyroid Hormone
Renin

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Hu, M. C., Kuro-o, M., & Moe, O. W. (2013). Klotho and chronic kidney disease. In Phosphate and Vitamin D in Chronic Kidney Disease (Vol. 180, pp. 47-63). S. Karger AG. https://doi.org/10.1159/000346778

Klotho and chronic kidney disease. / Hu, Ming C; Kuro-o, Makoto; Moe, Orson W.

Phosphate and Vitamin D in Chronic Kidney Disease. Vol. 180 S. Karger AG, 2013. p. 47-63.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hu, MC, Kuro-o, M & Moe, OW 2013, Klotho and chronic kidney disease. in Phosphate and Vitamin D in Chronic Kidney Disease. vol. 180, S. Karger AG, pp. 47-63. https://doi.org/10.1159/000346778
Hu MC, Kuro-o M, Moe OW. Klotho and chronic kidney disease. In Phosphate and Vitamin D in Chronic Kidney Disease. Vol. 180. S. Karger AG. 2013. p. 47-63 https://doi.org/10.1159/000346778
Hu, Ming C ; Kuro-o, Makoto ; Moe, Orson W. / Klotho and chronic kidney disease. Phosphate and Vitamin D in Chronic Kidney Disease. Vol. 180 S. Karger AG, 2013. pp. 47-63
@inbook{540c2962d880491b9b67b2bd0bd180af,
title = "Klotho and chronic kidney disease",
abstract = "Through alternative splicing, Klotho protein exists both as a secreted and a membrane form whose extracellular domain could be shed from the cell surface by secretases and released into the circulation to act as endocrine factor. Unlike membrane Klotho which functions as a coreceptor for fibroblast growth factor-23 (FGF23) to modulate FGF23 signal transduction, soluble Klotho is a multifunction protein present in the biological fluids including blood, urine and cerebrospinal fluid and plays important roles in antiaging, energy metabolism, inhibition of Wnt signaling, antioxidation, modulation of ion transport, control of parathyroid hormone and 1,25(OH) 2 VD 3 production, and antagonism of renin-angiotensin- aldosterone system. Emerging evidence from clinical and basic studies reveal that chronic kidney disease is a state of endocrine and renal Klotho deficiency, which may serve as an early biomarker and a pathogenic contributor to chronic progression and complications in chronic kidney disease including vascular calcification, cardiac hypertrophy, and secondary hyperparathyroidism. Supplementation of exogenous Klotho and/or upregulation of endogenous Klotho production by using rennin angiotensin system inhibitors, HMG CoA reductase inhibitors, vitamin D analogues, peroxisome proliferator-activated receptors- gamma agonists, or anti-oxidants may confer renoprotection from oxidation and suppression of renal fibrosis, and also on prevention or alleviation of complications in chronic kidney disease. Therefore, Klotho is a highly promising candidate on the horizon as an early biomarker, and as a novel therapeutic agent for chronic kidney disease.",
author = "Hu, {Ming C} and Makoto Kuro-o and Moe, {Orson W}",
year = "2013",
month = "5",
day = "2",
doi = "10.1159/000346778",
language = "English (US)",
isbn = "9783318023701",
volume = "180",
pages = "47--63",
booktitle = "Phosphate and Vitamin D in Chronic Kidney Disease",
publisher = "S. Karger AG",

}

TY - CHAP

T1 - Klotho and chronic kidney disease

AU - Hu, Ming C

AU - Kuro-o, Makoto

AU - Moe, Orson W

PY - 2013/5/2

Y1 - 2013/5/2

N2 - Through alternative splicing, Klotho protein exists both as a secreted and a membrane form whose extracellular domain could be shed from the cell surface by secretases and released into the circulation to act as endocrine factor. Unlike membrane Klotho which functions as a coreceptor for fibroblast growth factor-23 (FGF23) to modulate FGF23 signal transduction, soluble Klotho is a multifunction protein present in the biological fluids including blood, urine and cerebrospinal fluid and plays important roles in antiaging, energy metabolism, inhibition of Wnt signaling, antioxidation, modulation of ion transport, control of parathyroid hormone and 1,25(OH) 2 VD 3 production, and antagonism of renin-angiotensin- aldosterone system. Emerging evidence from clinical and basic studies reveal that chronic kidney disease is a state of endocrine and renal Klotho deficiency, which may serve as an early biomarker and a pathogenic contributor to chronic progression and complications in chronic kidney disease including vascular calcification, cardiac hypertrophy, and secondary hyperparathyroidism. Supplementation of exogenous Klotho and/or upregulation of endogenous Klotho production by using rennin angiotensin system inhibitors, HMG CoA reductase inhibitors, vitamin D analogues, peroxisome proliferator-activated receptors- gamma agonists, or anti-oxidants may confer renoprotection from oxidation and suppression of renal fibrosis, and also on prevention or alleviation of complications in chronic kidney disease. Therefore, Klotho is a highly promising candidate on the horizon as an early biomarker, and as a novel therapeutic agent for chronic kidney disease.

AB - Through alternative splicing, Klotho protein exists both as a secreted and a membrane form whose extracellular domain could be shed from the cell surface by secretases and released into the circulation to act as endocrine factor. Unlike membrane Klotho which functions as a coreceptor for fibroblast growth factor-23 (FGF23) to modulate FGF23 signal transduction, soluble Klotho is a multifunction protein present in the biological fluids including blood, urine and cerebrospinal fluid and plays important roles in antiaging, energy metabolism, inhibition of Wnt signaling, antioxidation, modulation of ion transport, control of parathyroid hormone and 1,25(OH) 2 VD 3 production, and antagonism of renin-angiotensin- aldosterone system. Emerging evidence from clinical and basic studies reveal that chronic kidney disease is a state of endocrine and renal Klotho deficiency, which may serve as an early biomarker and a pathogenic contributor to chronic progression and complications in chronic kidney disease including vascular calcification, cardiac hypertrophy, and secondary hyperparathyroidism. Supplementation of exogenous Klotho and/or upregulation of endogenous Klotho production by using rennin angiotensin system inhibitors, HMG CoA reductase inhibitors, vitamin D analogues, peroxisome proliferator-activated receptors- gamma agonists, or anti-oxidants may confer renoprotection from oxidation and suppression of renal fibrosis, and also on prevention or alleviation of complications in chronic kidney disease. Therefore, Klotho is a highly promising candidate on the horizon as an early biomarker, and as a novel therapeutic agent for chronic kidney disease.

UR - http://www.scopus.com/inward/record.url?scp=84925735151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925735151&partnerID=8YFLogxK

U2 - 10.1159/000346778

DO - 10.1159/000346778

M3 - Chapter

C2 - 23652549

AN - SCOPUS:84925735151

SN - 9783318023701

SN - 9783318023695

VL - 180

SP - 47

EP - 63

BT - Phosphate and Vitamin D in Chronic Kidney Disease

PB - S. Karger AG

ER -